News brief­ing: Gilead sub­mits fil­go­tinib to Eu­ro­pean reg­u­la­tors for UC; GW Phar­ma­ceu­ti­cals launch­es PhI­II tri­al for MS can­di­date made with cannabis ex­tracts

Gilead’s fil­go­tinib is get­ting a chance at a new in­di­ca­tion in Eu­rope af­ter the US reg­u­la­tors hand­ed down a CRL a few months ago.

The com­pa­ny an­nounced Mon­day af­ter­noon that the EMA is tak­ing up a sec­ond re­view for the JAK1 in­hibitor, this time in ul­cer­a­tive col­i­tis. Mar­ket­ed as Jy­s­e­le­ca on the con­ti­nent, fil­go­tinib has al­ready been ap­proved for adults with mod­er­ate to se­vere rheuma­toid arthri­tis who are re­sis­tant to oth­er an­ti-rheumat­ic drugs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.